Published in Women's Health Weekly, October 26th, 2000
Orphan drug designation for O-Vax entitles AVAX to exclusive marketing rights in the United States on that vaccine for seven years following marketing approval, and enables the company to obtain research funding, tax credits for certain research expenses, and a waiver from the application user fee.
AVAX is conducting a Phase II multicenter clinical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.